People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

美股开盘：三大指数集体高开。美股三大指数集体高开，道指涨0.44%，纳指涨0.57%，标普500指数涨0.31%。芯片公司Marvell涨近16%，AI需求强劲，公司销售额环比增19%，大超预期。礼来涨近2%，礼来减肥药Zepbound在首次对比试验中超越诺和诺德的Wegovy。

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

礼来公司表示，在对比试验中，Zepbound的相对减重效果比Wegovy高出47%。该公司还称，使用Zepbound的人中超过31%的人减掉了至少四分之一的体重，而使用Wegovy的人中只有约16%的人减掉了这么多的体重。

WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

礼来公司近期公布的一项研究结果显示，其减肥药Zepbound在与诺和诺德的Wegovy的首次临床试验中比较重表现更加优异。在礼来资助的一项临床试验中，使用Zepbound的参与者在72周内平均减轻了20%的体重，而使用诺和诺德的Wegovy的参与者减 ...